Kazia CFO James E. Levine files Form 3

Kazia Therapeutics Ltd director-level insider James E. Levine, the company’s Chief Financial Officer, has filed a Form 3 initial statement of beneficial ownership.

Rhea-AI Filing Summary

Kazia Therapeutics Ltd director-level insider James E. Levine, the company’s Chief Financial Officer, has filed a Form 3 initial statement of beneficial ownership. The provided data show no reported purchases, sales, exercises, gifts, or other transactions, reflecting only his status as a reporting officer.

Key Terms

Chief Financial Officer, reporting person, beneficial ownership

3 terms

Chief Financial Officer financial

"his listed title is Chief Financial Officer"

A Chief Financial Officer (CFO) is the person in charge of a company's money and financial planning. They decide how to spend, save, and invest funds to help the company grow and stay stable. Their role is important because good financial decisions keep the company healthy and successful.

reporting person regulatory

"shows that James E. Levine is a reporting person for Kazia Therapeutics"

beneficial ownership regulatory

"Form 3 initial statement of beneficial ownership"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Kazia Therapeutics (KZIA) Form 3 filing show?

The Form 3 shows that James E. Levine is a reporting person for Kazia Therapeutics as its Chief Financial Officer. The transaction summary in the provided data reports zero buys, sells, exercises, gifts, or other transactions associated with this initial ownership statement.

Who is the insider named in Kazia Therapeutics (KZIA) Form 3?

The insider is James E. Levine, identified as an officer of Kazia Therapeutics. His listed title is Chief Financial Officer, and he is not reported as a director or ten percent owner in this Form 3 data excerpt.

Does the Kazia Therapeutics (KZIA) Form 3 report any share purchases or sales?

The transaction summary in the provided Form 3 data shows zero buyCount and zero sellCount, with netBuySellShares at 0. This indicates no reported purchases or sales of Kazia Therapeutics securities in this initial ownership statement excerpt.

Are there any derivative exercises or gifts in the Kazia Therapeutics (KZIA) Form 3?

The Form 3 transactionSummary lists exerciseCount, giftCount, and derivativeTransactionCount all as 0. This means no derivative exercises, gifts, or other derivative transactions are reported in the provided portion of this initial beneficial ownership filing.

What role does James E. Levine hold at Kazia Therapeutics (KZIA) in this Form 3?

James E. Levine is identified as an officer of Kazia Therapeutics with the title Chief Financial Officer. He is not flagged as a director or ten percent owner, making him a reporting person due to his executive officer position at the company.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/15/2026 - 06:52 PM EDT Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Levine James E.

(Last) (First) (Middle)

THREE INTERNATIONAL TOWERS

LEVEL 24, 300 BARANGAROO AVE

(Street)

SYDNEY, NSW 2000

(City) (State) (Zip)

AUSTRALIA

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
06/01/2026

3. Issuer Name and Ticker or Trading Symbol
KAZIA THERAPEUTICS LTD [ KZIA ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24 - Power of Attorney

No securities are beneficially owned.

	/s/ James Levine	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)